SunTrust Banks started coverage on shares of Arcus Biosciences (NYSE:RCUS) in a research report released on Tuesday, Briefing.com Automated Import reports. The brokerage issued a buy rating and a $20.00 price objective on the stock.

Other research analysts have also issued research reports about the stock. Mizuho reaffirmed a buy rating and set a $22.00 price objective on shares of Arcus Biosciences in a research report on Monday, November 11th. ValuEngine raised shares of Arcus Biosciences from a hold rating to a buy rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research lowered shares of Arcus Biosciences from a buy rating to a hold rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Arcus Biosciences presently has an average rating of Buy and an average price target of $17.35.

Shares of RCUS traded down $0.32 during trading hours on Tuesday, reaching $7.65. 72,356 shares of the company traded hands, compared to its average volume of 248,848. The stock’s fifty day moving average is $8.29 and its 200 day moving average is $8.45. The stock has a market cap of $366.41 million, a P/E ratio of -5.35 and a beta of 0.99. Arcus Biosciences has a 1-year low of $6.30 and a 1-year high of $13.77.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.51) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.02). The company had revenue of $1.75 million for the quarter, compared to analyst estimates of $1.34 million. Arcus Biosciences had a negative net margin of 1,180.37% and a negative return on equity of 38.73%. Sell-side analysts predict that Arcus Biosciences will post -2.19 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the stock. GSA Capital Partners LLP increased its holdings in shares of Arcus Biosciences by 17.3% during the second quarter. GSA Capital Partners LLP now owns 16,243 shares of the company’s stock worth $129,000 after buying an additional 2,392 shares in the last quarter. Aperio Group LLC acquired a new stake in shares of Arcus Biosciences during the second quarter worth approximately $32,000. Meeder Asset Management Inc. increased its holdings in shares of Arcus Biosciences by 672.9% during the third quarter. Meeder Asset Management Inc. now owns 4,939 shares of the company’s stock worth $46,000 after buying an additional 4,300 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Arcus Biosciences by 10.5% during the third quarter. Rhumbline Advisers now owns 48,859 shares of the company’s stock worth $445,000 after buying an additional 4,660 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Arcus Biosciences by 32.9% during the third quarter. Russell Investments Group Ltd. now owns 21,315 shares of the company’s stock worth $195,000 after buying an additional 5,278 shares in the last quarter. 46.83% of the stock is owned by hedge funds and other institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.

Featured Story: Trading based on a resistance level

Analyst Recommendations for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.